Documented batches Public COA verification Research use only Quality standards
Primal Platform
← Back to all peptide profiles
Mitochondrial peptide Approval and post-marketing data Human data available

Peptide database · P-027

Elamipretide

SS-31; MTP-131; Forzinity

Elamipretide is a mitochondria-targeting tetrapeptide that received accelerated U.S. approval in 2025 for a specific rare disease.

01

Molecular profile

Molecular profile

Molecule class
Mitochondrial peptide
Origin
Synthetic
Primary target system
Cardiolipin-assoziierte mitochondriale Membranprozesse
Development stage
Authorised active substance
Structure note

Aromatisch-kationisches Tetrapeptid mit mitochondrialer Membranaffinität.

02

Mechanism and signalling

Mechanism and signalling

The peptide is associated with cardiolipin and stabilisation of mitochondrial membrane and electron-transport processes.

03

Scientific classification

Scientific classification

This profile maps Elamipretide to the research areas mitochondrial, rare_disease. Molecule class, evidence level, development stage and regulatory status are separated so that preclinical findings are not confused with authorised uses.

Mitochondria and longevity research

Mitochondrial peptides, cellular stress, bioenergetics and age-associated pathways.

Rare diseases and precision medicine

Peptide therapeutics for molecularly defined rare diseases and specialised treatment concepts.

04

Evidence base

Approval and post-marketing data

PreclinicalEarly human dataClinical dataPhase IIPhase IIIApproval and post-marketing data

Alongside earlier heterogeneous programmes, an FDA accelerated approval is in place; confirmatory studies remain part of regulatory obligations.

05

Regulatory status

Specifically approved in the U.S.

Specifically approved in the U.S.

The substance has a specific U.S. approval. This does not constitute general authorisation in Germany or the European Union, nor approval of unlicensed products.

06

Safety and use notice

No dosing or administration recommendation

The available evidence does not establish safe self-directed use. This profile intentionally provides no dosing, sourcing or administration guidance.

07

Sources and registries

Sources and registries